EGFR and colorectal carcinoma: Another concern about using EGFR inhibitors is the fact that in patients with CRC, the presence of kras mutations seems to be negatively corelated to response to anti-EGFR therapy and only patients with wild-type ras tumors receive a clinical benefit from anti-EGFR antibody therapy [84].